Beijing Gene+ Technology
Empowering Cancer Prevention and Early Detection with Advanced Gene Testing Services
Empowering Cancer Prevention and Early Detection with Advanced Gene Testing Services
Beijing Gene+ Technology, also known as Beijing Gene Plus, is a prominent player in the health care and life sciences industries. The company, founded in 2015, has a compelling slogan: "Empowering Cancer Prevention and Early Detection with Advanced Gene Testing Services." The core focus of Beijing Gene+ is to offer gene testing services targeted at cancer prevention and early detection, delivering vital data to bolster the implementation of precision medicine.
Operating in approximately 100 hospitals, Beijing Gene+ has made significant strides in serving thousands of cancer patients across China. The company finalized a noteworthy CNY750.00M Series C investment on 22 July 2021, attracting backing from a roster of esteemed investors including GGV Capital, CCB International, Harvest Capital Management, Baidu Venture, Fortune Capital, CCB Capital, and Alibaba Health Information Technology.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | CNY750.00M | 7 |
|
22 Jul 2021 |
| Series B | $28.00M | 3 |
|
30 Sep 2019 |
| Venture Round | CNY50.00M | - | 14 Jan 2019 | |
| Series A | $30.00M | - | 14 Sep 2016 |
No recent news or press coverage available for Beijing Gene+ Technology.
We care about your data, and we'd love to use cookies make your experience better.
